Research and Markets: Emerging Drug Discovery Technologies: Building Competitive Advantage Through Lab-on-a-Chip, Nanotechnology and RNAi

    DUBLIN, Ireland, May 6 /PRNewswire/ -- Research and Markets
 (http://www.researchandmarkets.com/reports/c17061 ) has announced the addition
 of Emerging Drug Discovery Technologies: Building competitive advantage
 through lab-on-a-chip, nanotechnology and RNAi to their offering.
      (Logo:  http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH )
     Emerging Drug Discovery Technologies: Building competitive advantage
 through lab-on-a-chip, nanotechnology and RNAi, is a new report which provides
 an in-depth analysis of three technological innovations that are being
 heralded to revolutionize the drug discovery process by rapidly expediting
 drug discovery research. This report focuses on lab-on-a-chip (LOC) devices,
 nanotechnology and RNA interference drug discovery technologies that are
 increasingly being used to identify novel drug targets and to successfully
 reduce R&D timelines.
 
     This report also provides:
     - In-depth analysis of the market forces
     - Current and future technological advances
     - Detailed company profiles
     - Eight year forecasts of market size for LOC devices, nanotechnology in
 drug discovery and RNA interference technologies and therapeutics
 
     Key Findings of the Report:
 
     - The markets for LOC devices, nanotechnology, and RNAi technologies and
 therapeutics are set to experience phenomenal growth rates, driven
 by novel product developments and new market entrants.
 
     - The nanotechnology market is forecast to reach $955m by 2012, a CAGR
 (2004-2012) of 28.3%, while the LOC/microfluidics market is projected to
 generate sales of $1,530m in 2012, a CAGR of 35.5%. The larger RNAi market is
 predicted to be worth $1.1bn in 2012, although its CAGR is lower at 16.1%.
 
     - Some of the major factors driving growth and expansion of the LOC device
 market include: high throughput screening, increased automation, reduction in
 sample requirement, reduced exposure to hazardous materials, and the increased
 rate at which potential drug
 targets are screened.
 
     - At an embryonic stage of development, nano-enabled drugs are already
 bringing clinical benefits to thousands of patients. Two examples are Abraxane
 for the treatment of metastatic breast cancer, and RenaZorb, which provides
 phosphate control in kidney dialysis patients
 
     - The resolution of several patent and licensing disputes, which
 threatened to halt the growth and expansion of the RNAi field, is now allowing
 more companies to enter the RNAi field. This is expected to further boost RNAi
 market growth in the future.
 
 
     Key questions answered in this report
 
     - What will the market for lab-on-a-chip (LOC), nanoenabled drug discovery
 and RNAi technology be worth in 2012?
 
     - How can these three technologies be effectively applied in the drug
 discovery process?
 
     - What are the major factors driving and restraining market expansion of
 these technologies in drug discovery?
 
     - Who are the leading players within each of the three markets and how
 competitive or fragmented are the markets?
 
     - Which pharmaceutical and biotech companies are investing in lab-on-a-
 chip (LOC), nanotechnology and RNAi, and what strategic alliances,
 partnerships and agreements have been formed during the last few years?
 
 
     Top five reasons to read this report today:
 
     1.) Gain insight into new technological developments in LOC devices,
 nanotechnology and RNAi and their applications in the pharmaceutical industry
 to develop new drugs.
 
     2.) Improve productivity and reduce R&D expenditure by understanding how
 LOC devices, nanotechnology and RNAi technology can be applied to all stages
 of the drug development process.
 
     3.) Review in-depth analysis of strategic alliances, acquisitions and
 agreements between pharmaceutical/biotech companies and LOC, nanotechnology
 and RNAi vendors.
 
     4.) Understand where LOC devices, nanotechnology and RNAi have already
 impacted the identification of new drug targets and biomarkers for diagnosis
 screening.
 
     5.) Highlight the efficacy and potential long-term cost effectiveness of
 LOC devices, nanotechnology and RNAi for drug discovery.
 
 
     Companies mentioned inside this report include the following:-
 
     - Aclara BioSciences
     - Advion BioSciences, Inc.
     - Agilent Technologies
     - BioMicro Systems
     - BioTrove Inc.
     - Caliper Life Sciences
     - Cepheid
     - CombiMatrix Corp.
     - Eksigent Technologies
     - Epigem Limited
     - Fluidigm Corp.
     - Gyros AB
     - Nanogen
     - Nanostream Inc.
     - Protiveris
     - Sequenom
     - Zyomyx
     - 3DM Inc.
     - Alnis Biosciences Inc.
     - American Pharmaceuticals Partners Inc.
     - BioCrystal Ltd.
     - BioForce NanoSciences Inc.
     - CrystalPlex Corp.
     - C Sixty Inc.
     - Evident Technologies, Inc.
     - NanBio Corp.
     - Nanosphere
     - PharmaSeq, Inc
     - Quantum Dot Corp.
     - Ambion
     - Alnylam Pharmaceuticals, Inc.
     - Benitec Ltd
     - CytRx Corp.
     - Cenix BioScience
     - Devgen
     - Dharmacon, Inc.
     - Eurogentec (EGT)
     - Imgenex Corp.
     - Immusol Inc.
     - Invitrogen Corp.
     - InvivoGen
     - MWG Biotech
     - Proligo
     - Promega
     - Qiagen.
     - Sirna Therapeutics
 
 
     For more information visit
 http://www.researchandmarkets.com/reports/c17061
 
     Laura Wood
     Senior Manager
     Research and Markets
     press@researchandmarkets.com
     Fax: +353 1 4100 980
 
 

SOURCE Research and Markets

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.